Starting from the categorical definition of "Internet Gaming Disorder" in young people and adolescent, we proceeded to list the individual characteristics, with particular attention to the statistical, clinical, neurobiological and therapeutic profiles, concluding the analysis of the possible strategies to be used to finalize the resolutions to the problems, arising from the disturbance in question.

Background: Cannabinoid Hyperemesis Syndrome (CHS) is characterized by cyclic vomiting and compulsive need to take hot showers in the context of chronic cannabis use. Physicians lack of knowledge of CHS often results in a diagnostic delay of several years. The purpose of this article is to describe CHS in order to enable physicians, and more particularly psychiatrists, to diagnose it as quickly as possible and thus avoid unnecessary additional invasive examinations. Subjects and methods: Bibliographic search for scientific articles published between 2004 and 2019 in the Cochrane, Medline, PubMed, and Psycinfo databases. Key words used were "hyperemesis", "cannabis", "cannabinoid". Results: CHS is associated with chronic cannabis use and typically manifests as incoercible cyclical vomiting, diffuse abdominal pain, and relief of symptoms by taking hot showers. Patients suffering from CHS generally visit emergency departments very regularly and undergo numerous additional examinations, both invasive and unnecessary. Since no organic cause can explain these symptoms, these patients are referred to the psychiatry department. The only curative treatment is the complete cessation of cannabis use. Conclusion: CHS is an under-diagnosed pathology because it is little known to physicians. This syndrome has unique clinical characteristics. Early recognition of CHS avoids repeated visits to the emergency room and unnecessary follow-up examinations.

Recent increases in mortality from overdoses in the US have been primarily driven by deaths due to the more potent synthetic opioids. Naloxone is an effective countermeasure to treat opioid overdose. We compared the pharmacokinetics of the three available doses of naloxone used to treat prehospital opioid overdoses. Overall, the systemic exposures of 2 mg intramuscular and 4 mg intranasal of naloxone appear to be similar. By comparison, the exposure levels of the 5 mg dose intramuscular naloxone (ZIMHI) appears to be greater and more rapid. These results support the notion that higher doses of naloxone result in greater bioavailability which may be required for reversal due to the more potent synthetic opioids, such as fentanyl.